The firm is expecting Phase III readouts this year for its FGFR2b drug bemarituzumab and is advancing a second KRAS inhibitor to the clinic.

The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates ...

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

A team of researchers from the Keck School of Medicine of USC has developed an advanced tool for analyzing chimeric antigen ...

Q1 2025 Management View CEO Stephane Bancel highlighted that Q1 revenues were $0.1 billion, with a net loss of $1 billion, ...

Experts champion medically integrated care and oncology optimized distribution models as vital strategies to improve outcomes, streamline access, and reduce costs for patients.

BOSTON and LONDON, May 01, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced ...

Here's a list of the companies that have announced new U.S. investments since Trump took office: Merck on Tuesday said it is ...

In this week’s edition of InnovationRx, we look at a patent fight over the world’s top-selling drug, breakthroughs from the ...

Business & Finance Media Group in partnership with Ibec has launched the Top 100 Companies Leading In Wellbeing Index 2025.

The company said it took financial hits from the Inflation Reduction Act's Medicare Part D redesign, which included higher ...